AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2123072 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) (group A)
Number of subjects: 60
Study 2123072 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) (group B)
Number of subjects: 60
Study 360249 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (300-600 mg daily for six weeks)
Number of subjects: 10
Study 360249 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 10
Study 31324444 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin induction with tacrolimus and/or mycophenolate mofetil maintenance, steroids not used beyond 1 week
Number of subjects: 186
Study 28168363 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor at 38 weeks
Number of subjects: 100
Study 28168363 — intervention group
Group type: COMPARATOR
Intervention: Induction of labor at 40 weeks
Number of subjects: 100
Study 24698092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue‐induced alcohol craving measured with visual analogue scales at 60 days of abstinence.
Number of subjects: 319
Study 24698092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue‐induced alcohol craving measured with visual analogue scales at 7, 14, and 30 days of abstinence.
Number of subjects: 319
Study 24698092 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate, blood pressure, and skin conductance responses at 7, 14, 30, and 60 days of abstinence.
Number of subjects: 319
Study 23175622 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (IM) interruption and rechallenge
Number of subjects: 71
Study 21757321 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Control Measurement Scale (TCMS)
Number of subjects: 26
Study 19086714 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal irrigation for 10 weeks
Number of subjects: 62
Study 16116596 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist treatment
Number of subjects: 65
Study 12384828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program including intensive lifestyle management and frequent telephone counseling.
Number of subjects: 2205
Study 12384828 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CON)
Number of subjects: 2205
Study 10419922 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 7.5 mg/wk
Number of subjects: 60
Study 10419922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8543521 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary diagnosis of major depression, anxiety, disruptive disorders, substance use
Number of subjects: 236
Study 8543521 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary dysthymia
Number of subjects: 236
Study 8543521 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of onset of disorder
Number of subjects: 236
Study 8543521 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission intervals between episodes (well time)
Number of subjects: 236
Study 2186776 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine 100 mg q.d.s. orally for 4 weeks
Number of subjects: 50
Study 2186776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6157256 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 168
Study 6157256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 168
Study 6157256 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 168
Study 31002954 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 540
Study 31002954 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 540
Study 28162984 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg to 300 mg)
Number of subjects: 90
Study 28162984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25359121 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rating of the effects of alcohol (SRE) questionnaire
Number of subjects: 163
Study 25359121 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of relationship breakups
Number of subjects: 163
Study 23537982 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine early percutaneous coronary intervention (r-PCI)
Number of subjects: 0
Study 23537982 — intervention group
Group type: COMPARATOR
Intervention: Standard approach of performing early PCI only for failed fibrinolysis (s-PCI)
Number of subjects: 0
Study 21709064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adeno‐associated virus type 1/sarcoplasmic reticulum Ca(2+)‐ATPase
Number of subjects: 39
Study 21709064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 19455177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 120,000 U in fifth and seventh gestational months (Group C)
Number of subjects: 139
Study 19455177 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol 60,000 U in fifth month of gestation (Group B)
Number of subjects: 139
Study 19455177 — intervention group
Group type: COMPARATOR
Intervention: No cholecalciferol (Group A)
Number of subjects: 139
Study 16704893 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (PSA testing)
Number of subjects: 4278
Study 16704893 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 4278
Study 16278621 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education and an educational booklet on the first day of therapy, counseling in the third and sixth months
Number of subjects: 119
Study 16278621 — intervention group
Group type: COMPARATOR
Intervention: No counseling or education
Number of subjects: 119
Study 12036860 — intervention group
Group type: COMPARATOR
Intervention: Gemtuzumab ozogamicin (GO) without IL-11
Number of subjects: 51
Study 12036860 — intervention group
Group type: COMPARATOR
Intervention: Gemtuzumab ozogamicin (GO) with IL-11
Number of subjects: 51
Study 12036860 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin plus continuous-infusion, high-dose cytosine arabinoside (IA)
Number of subjects: 51
Study 12036860 — intervention group
Group type: COMPARATOR
Intervention: Gemtuzumab ozogamicin (GO) with or without IL-11
Number of subjects: 51
Study 10550850 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 6% SAZN
Number of subjects: 0
Study 10550850 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1% SAZN
Number of subjects: 0
Study 10550850 — intervention group
Group type: COMPARATOR
Intervention: Diprivan‐10
Number of subjects: 0
Study 7832595 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient antioxidants (alpha‐tocopherol and beta‐carotene)
Number of subjects: 0
Study 7832595 — intervention group
Group type: COMPARATOR
Intervention: Ongoing randomized trials of primary and secondary prevention
Number of subjects: 0
Study 2126652 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term occlusive dressing (24h)
Number of subjects: 36
Study 2126652 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged occlusion (5-28 days)
Number of subjects: 36
Study 2126652 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal prolonged occlusion dressing
Number of subjects: 36
Study 7000222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (300 mg intramuscularly per week)
Number of subjects: 42
Study 7000222 — intervention group
Group type: COMPARATOR
Intervention: Oestradiol undecylate (100 mg intramuscularly per month)
Number of subjects: 42
Study 31340598 — intervention group
Group type: EXPERIMENTAL
Intervention: NoTrap! program (experimental group)
Number of subjects: 622
Study 31340598 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 622
Study 28135221 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-body cryotherapy (PBC) for 150 seconds at -130 to -160° C
Number of subjects: 200
Study 28135221 — intervention group
Group type: COMPARATOR
Intervention: Control group in a thermo neutral room (22.0 ± 0.5° C)
Number of subjects: 200
Study 26319124 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 41
Study 26319124 — intervention group
Group type: COMPARATOR
Intervention: Open technique
Number of subjects: 41
Study 23799886 — intervention group
Group type: EXPERIMENTAL
Intervention: e-CUIDATE (telerehabilitation with exercise planning including breathing exercises, mobility, strength, and stretching)
Number of subjects: 0
Study 23799886 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group maintaining their usual routine)
Number of subjects: 0
Study 23799886 — intervention group
Group type: EXPERIMENTAL
Intervention: e-CUIDATE
Number of subjects: 0
Study 23799886 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22551481 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP: peripheral nerve blockage with 80mg of lidocaine, 100mg of mepivacaine and 25mg of levobupivacaine
Number of subjects: 111
Study 22551481 — intervention group
Group type: COMPARATOR
Intervention: INF: surgical wound infiltration with 50mg of levobupivacaine
Number of subjects: 111
Study 22551481 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 111
Study 22551481 — intervention group
Group type: COMPARATOR
Intervention: INF
Number of subjects: 111
Study 19337061 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme 'to live with the sun' taught by teachers
Number of subjects: 282
Study 19337061 — intervention group
Group type: COMPARATOR
Intervention: Control group (B) with no educational programme
Number of subjects: 282
Study 17533053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucoidan ingestion (galactofucan sulfate)
Number of subjects: 0
Study 15159645 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource Mother group (RM group)
Number of subjects: 50
Study 15159645 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 15159645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 11917446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine jelly at 2%
Number of subjects: 90
Study 11917446 — intervention group
Group type: COMPARATOR
Intervention: Chlorexidine gluconate
Number of subjects: 90
Study 9722227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate 0.1 mg o.d. (n=26)
Number of subjects: 63
Study 9722227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate 0.2 mg o.d. (n=25)
Number of subjects: 63
Study 9722227 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 63
Study 9722227 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=6)
Number of subjects: 63
Study 9722227 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (n=44)
Number of subjects: 63
Study 8036306 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 216
Study 8036306 — intervention group
Group type: COMPARATOR
Intervention: Control (no inhaled steroids)
Number of subjects: 216
Study 2730826 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiluted i.m. preparation (25 mg ml‐1)
Number of subjects: 149
Study 2730826 — intervention group
Group type: COMPARATOR
Intervention: Diluted i.m. preparation in normal saline (5 mg ml‐1)
Number of subjects: 149
Study 30996379 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate
Number of subjects: 150
Study 30996379 — intervention group
Group type: COMPARATOR
Intervention: Stannous fluoride
Number of subjects: 150
Study 30996379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 30078892 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression with fusion
Number of subjects: 139
Study 30078892 — intervention group
Group type: COMPARATOR
Intervention: Decompression alone
Number of subjects: 139
Study 27770150 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-step mandibular advancement group (SSG)
Number of subjects: 51
Study 27770150 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise mandibular advancement group (SWG)
Number of subjects: 51
Study 27770150 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 51
Study 24450365 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 N mobilization
Number of subjects: 64
Study 24450365 — intervention group
Group type: COMPARATOR
Intervention: 30 N mobilization
Number of subjects: 64
Study 24450365 — intervention group
Group type: COMPARATOR
Intervention: Placebo (detuned laser)
Number of subjects: 64
Study 22183215 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 59
Study 22183215 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 59
Study 20379194 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training
Number of subjects: 65
Study 20379194 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise training
Number of subjects: 65
Study 20379194 — intervention group
Group type: COMPARATOR
Intervention: Control (sedentary routine)
Number of subjects: 65
Study 20379194 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous and interval exercise training
Number of subjects: 65
Study 17647115 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph II (HRT) parameters
Number of subjects: 450
Study 17647115 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard automated perimetry (SAP)
Number of subjects: 450
Study 17647115 — intervention group
Group type: COMPARATOR
Intervention: Ocular hypertensive group
Number of subjects: 450
Study 16091396 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg/6 weeks)
Number of subjects: 20
Study 11943439 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 104
Study 11943439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 10676476 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium concentration in serum (55 +/- 11 micrograms Se/L)
Number of subjects: 470
Study 10676476 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium concentration in hair (0.268 +/- 0.040 microgram Se/g)
Number of subjects: 470
Study 10676476 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium concentration in urine (12 +/- 5 micrograms Se/L)
Number of subjects: 470
Study 7573869 — intervention group
Group type: EXPERIMENTAL
Intervention: Different end-tidal carbon dioxide and volatile agent concentrations during maintenance of anaesthesia
Number of subjects: 60
Study 2147813 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg/day
Number of subjects: 1785
Study 2147813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1785
Study 2147813 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (combined results from meta-analysis)
Number of subjects: 1785
Study 7452472 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium salicylate
Number of subjects: 18
Study 7452472 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate
Number of subjects: 18
Study 7452472 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 18
Study 29756749 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen oral spray
Number of subjects: 150
Study 29756749 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride oral spray
Number of subjects: 150
Study 29756749 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 150
Study 30420364 — intervention group
Group type: EXPERIMENTAL
Intervention: OMSC+ (OMSC plus performance coaching)
Number of subjects: 166
Study 30420364 — intervention group
Group type: COMPARATOR
Intervention: OMSC (control group)
Number of subjects: 166
Study 27115264 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention including daily checklist and goal setting during multidisciplinary rounds with follow‐up clinician prompting for 11 care processes
Number of subjects: 6761
Study 27115264 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 6761
Study 27115264 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 6761
Study 25214161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education and supplemental iron administration (iron polymaltose complex)
Number of subjects: 310
Study 25214161 — intervention group
Group type: COMPARATOR
Intervention: Standard information on prevention of IDA (Control group)
Number of subjects: 310
Study 25214161 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron medication for >6 months
Number of subjects: 310
Study 25214161 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding for >6 months
Number of subjects: 310
Study 23110608 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient Brief Psychodynamic Psychotherapy
Number of subjects: 130
Study 23110608 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 130
Study 21190574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 330
Study 21190574 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 330
Study 17285386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg after induction of anesthesia
Number of subjects: 160
Study 17285386 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg just before the end of anesthesia
Number of subjects: 160
Study 17285386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg after induction of anesthesia and Metoclopramide 10 mg before the end of anesthesia
Number of subjects: 160
Study 17285386 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo)
Number of subjects: 160
Study 16583989 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Antibiotic Therapy (SAT) combined with amikacin
Number of subjects: 152
Study 16583989 — intervention group
Group type: COMPARATOR
Intervention: Other Antibiotic Therapy (OAT) combined with amikacin
Number of subjects: 152
Study 16583989 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin used in high once daily dose (HODD) with SAT or OAT
Number of subjects: 152
Study 16583989 — intervention group
Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 152
Study 16583989 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin HODD with TDM
Number of subjects: 152
Study 16583989 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin HODD without TDM
Number of subjects: 152
Study 16583989 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct costs of treatment with SAT
Number of subjects: 152
Study 16583989 — intervention group
Group type: COMPARATOR
Intervention: Direct costs of treatment with OAT
Number of subjects: 152
Study 16583989 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization costs per patient
Number of subjects: 152
Study 16583989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost reduction by omitting TDM in patients without risk factors
Number of subjects: 152
Study 16583989 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cost reduction by introducing safe and cheap standard treatment
Number of subjects: 152
Study 11966929 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMD) applied in test subjects
Number of subjects: 166
Study 11966929 — intervention group
Group type: COMPARATOR
Intervention: Control group without EMD
Number of subjects: 166
Study 10712814 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg
Number of subjects: 28
Study 10712814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8818069 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 1182
Study 8818069 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1182
Study 8818069 — intervention group
Group type: EXPERIMENTAL
Intervention: School-only and school-plus-family intervention groups
Number of subjects: 1182
Study 1600043 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient antioxidant therapy (600 micrograms organic selenium, 9000 i.u. beta-carotene, 0.54 g vitamin C, 270 i.u. vitamin E, 2 g methionine)
Number of subjects: 20
Study 1600043 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient antioxidant therapy
Number of subjects: 20
Study 1600043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3901731 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate liquid
Number of subjects: 29
Study 3901731 — intervention group
Group type: COMPARATOR
Intervention: Placebo liquid
Number of subjects: 29
Study 30871594 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 28 ± 2 days
Number of subjects: 0
Study 30871594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30871594 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study 30643068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine combined with extended-release methylphenidate (MPH-ER)
Number of subjects: 44
Study 30643068 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine and placebo
Number of subjects: 44
Study 27789196 — intervention group
Group type: EXPERIMENTAL
Intervention: Local consolidative therapy (chemo/radiotherapy or resection of all lesions)
Number of subjects: 74
Study 27789196 — intervention group
Group type: COMPARATOR
Intervention: Maintenance treatment alone (could be observation)
Number of subjects: 74
Study 24745634 — intervention group
Group type: EXPERIMENTAL
Intervention: Low health literacy
Number of subjects: 844
Study 24745634 — intervention group
Group type: COMPARATOR
Intervention: Adequate health literacy
Number of subjects: 844
Study 22722530 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) 150 mg intramuscularly every 12 weeks for 24 weeks
Number of subjects: 84
Study 22722530 — intervention group
Group type: COMPARATOR
Intervention: Continuous oral contraceptive (OC) pills (ethinyl estradiol 0.03 mg and gestodene 0.075 mg) daily for 24 weeks
Number of subjects: 84
Study 20421832 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month moderate-intensity physical activity (PA) intervention
Number of subjects: 424